Transcript of Earnings Call held on October 22, 2026

Date: October 29, 2026 The Manager The Manager Listing Department Listing Department National Stock Exchange of India Limited (NSE) BSE Limited (BSE) Exchange Plaza, 5th Floor Phiroze Jeejeebhoy Towers Plot No. C/1, G-Block Dalal Street Bandra-Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code:544282 Symbol: SAGILITY Dear Sir/Ma’am, Subject: Transcript of Investors Call held on October 22, 2026 This is in continuation of the Investors/Analyst Webinar conducted on October 22, 2026, to discuss the unaudited financial results of the Company for the quarter and half year ended September 30, 2026. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby attach the transcript of the aforementioned webinar. This information is also available on the Company’s website https://sagility.com/ This is for your kind information and record. Thanking You, For Sagility Limited Satishkumar Sakharayapattana Seetharamaiah Company Secretary & Compliance Officer M.No. A16008 Encl: a/a Sagility Limited (Formerly Sagility India Limited) Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India Corporate Identification Number: L72900KA2021PLC150054 Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagility.com Sagility Limited. Q2 FY27 Earnings Conference Call Transcript Thursday, 22 October, 2026 at 7:30 pm MANAGEMENT • Ramesh Gopalan - Managing Director and Group CEO • Srinivas Rathnam Mattapalli – Executive Vice President and Group Chief Financial Officer MODERATOR • Siddharth Rangnekar - CDR India QUESTIONERS • Chirag Kachhadiya - Motilal Oswal • Rishi Jhunjhunwala - IIFL • Dipesh Mehta - Emkay Global • Rohit Thorat - Axis Capital • Vamshi Krishna - Kotak Institutional • Akshat Agarwal - Jefferies • Sujay Chavan - Prabhudas Lilladher • Vibhor Singhal - Nuvama • Madhuchanda Dey - MC Pro • Ruchi Mukhija - ICICI Securities Siddharth Rangnekar: Good evening and welcome to the Quarter Two FY '27 Earnings Webinar of Sagility Limited. This is Siddharth Rangnekar from CDR India, and I shall be your host for today. As a reminder, all attendee lines will be in the listen-only mode, and there shall be an opportunity for you to ask questions after the presentation concludes. Please note that this webinar is being recorded. To introduce the management we have with us today, Mr. Ramesh Gopalan, Managing Director and Group CEO; and Mr. Srinivas Mattapalli, Executive Vice President and Group Chief Financial Officer. Before we begin, I would like to state that some of the statements made on today's call could be forward-looking in nature and may involve certain risks and uncertainties. A detailed statement in this regard is available at the quarter two and H1 FY '27 earnings presentation that has been uploaded to the stock exchanges. I would now like to hand over the forum to Mr. Ramesh Gopalan to begin the proceedings of this webinar. Over to you. Ramesh Gopalan: Thank you, Siddharth. Good evening, everyone, and thank you for joining us for our Q2 FY '27 earnings call. U.S. healthcare is still navigating steep cost increases overall. However, many of the national payers reported a significant improvement in their profitability in the first half of 2026 as a result of right sizing of membership and decrease in medical utilisation rates. In order to retain these margins, they need to continue to focus on managing medical costs, improving clinical and care outcomes, and driving operational efficiency. To help them achieve these objectives, they turn to large scale domain specialist players like Sagility, that combine deep healthcare expertise with AI capabilities and flexible partnership models, and greater accountability for outcomes. We are pleased with the progress that we have made through the first half of FY '27. The business momentum has been strong. We are expanding within our existing relationships. The clients we added in FY '26 are growing well, and our pipeline is robust. Let me start with what we are seeing in the market. Demand remains healthy, and clients are more deliberate in how they make decisions. Clients are prioritising investments that address immediate business pressures and show a clear path to measurable value. This is creating opportunities across our core business, managed services, and AI. For larger transformational deals, the buying process is more rigorous. More senior stakeholders are involved, and clients want a compelling business Page | 2 case, clear evidence of value, and confidence that their partner can execute at scale. Increasingly, they are choosing partners who combine deep domain expertise with practical AI and a willingness to take accountability for outcomes. Our pipeline reflects the shift. It includes more managed service deals and a healthy set of opportunities with Blues and other mid- market plans. This quarter, we won a large payment integrity engagement from a Big Ten health plan covering over 10 million members. This win demonstrates our growing ability to secure larger, higher value engagements. The deal has a minimum potential of over $10 million in ACV and could possibly be much more. In payment integrity deals, which are contingency-based linked to payment recovery, revenue will build progressively over time. Our other managed services deals are also progressing well. By their very nature, they take longer to negotiate and close, but they lead to deeper, longer- term relationships. AI is now central to these transformation conversations with clients. We are seeing this momentum translate into new SOW wins and more solutions moving into production. Our focus is on practical healthcare-specific solutions such as SmarTec Appeals Assist, Nurse Assist, and Claims Assist, which address real client priorities. We are gradually progressing from narrow AI use cases to a larger end-to-end workflow transformation using agentic AI. For example, for a client, we are implementing Synchrony Claims Lifecycle, an agentic workflow for claims adjudication, where multiple agents working in tandem with human in the loop handle extraction from unstructured inputs, drive workflows basis SOP for each scenario, do reasoning and decisioning, all of this in order to adjudicate a claim adhering to all compliance requirements. Similarly, in RCM, we are deploying Synchrony RCM Lifecycle, an agentic solution to handle denials, including identification, evidence collection, determination of appealability, and writing the appeal letters, again with humans reviewing at distinct checkpoints. We are also leveraging AI in how we go to market. It's helping us develop solutions faster, align more closely with client priorities, and have more strategic value focused conversations with clients. We are making progress on our other strategic priorities as well, broadening our capabilities across the healthcare value chain, and expanding our addressable market. The CareSeed acquisition announced last quarter is now integrated into our clinical practice. It Page | 3 strengthens our healthcare quality capabilities, particularly in the Medicare Advantage market, and gives us access to a broader base of mid- and small-sized clients. Yesterday, we announced the acquisition of Chirok Health LLC. Providers are a clear growth focus for us, and Chirok fits in line with that strategy. Chirok's mid-cycle revenue solutions are a natural complement to Sagility's proven front-end and back-end revenue cycle offerings, helping Sagility generate improved financial and operational outcomes for health providers from patient access through final payment. I will talk about Chirok a little more in detail later. Along with this, we are also scaling our provider go-to-market team to accelerate growth in the provider segment. With this, let me get into the specifics of our Q2 and H1 perfo [Showing first 8,000 characters — download PDF for full document]